Natural Product (NP) Details
General Information of the NP (ID: NP8519) | |||||
---|---|---|---|---|---|
Name |
Cepharanthine
|
||||
Synonyms |
Cepharanthin; (+)-Cepharanthine; O-Methylcepharanoline; Cepharantin; Cepharanthine [JAN]; UNII-7592YJ0J6T; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan; CHEBI:3546; 7592YJ0J6T; NSC623442; Cepharanthine (JAN); ecaene (non-preferred name); DSSTox_CID_25957; DSSTox_RID_81253; DSSTox_GSID_45957; C37H38N2O6; NSC-623442; CAS-481-49-2; CCRIS 6539; SR-01000779734; NSC 623442; BRN 0075231; Cepharanthin,(S); NCGC00095194-01; (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2~16,19~.1~3,10~.1~21,25~.0~4,8~.0~14,39~.0~31,35~]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dod; Cepharanthine (TN); Spectrum2_000832; Spectrum3_001963; 12-O-Methylcepharanoline; UPCMLD-DP054; BSPBio_003563; 4-27-00-09061 (Beilstein Handbook Reference); MLS000728518; SCHEMBL154545; SPECTRUM1505322; SPBio_000783; CHEMBL449782; DTXSID6045957; UPCMLD-DP054:001; KBio3_002909; Cepharanthine, >=95% (HPLC); Cepharanthine, >=98% (HPLC); HMS1922J12; HMS2232F21; Pharmakon1600-01505322; HY-N6972; Tox21_111483; BBL030154; BDBM50423643; CCG-40294; MFCD00210482; NSC758965; s4238; STK801907; ZINC30726863; AKOS004119865; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))-; Tox21_111483_1; MCULE-4243165865; NSC-758965; SDCCGMLS-0066893.P001; NCGC00161621-01; NCGC00161621-02; NCGC00161621-03; NCGC00161621-05; NCGC00161621-13; AC-15206; AK168069; AS-17451; SMR000445632; SBI-0207049.P001; CS-0007138; V0178; C09391; D01035; AB00643356_08; AB00643356_09; 481C492; Q-100524; SR-01000779734-3; SR-01000779734-4; BRD-K96194081-001-06-0; Q15410888; 6',12'-Dimethoxy-2,2'-dimethyl-6,7-[methylenebis-(oxy)]oxyacanthan; Oxyacanthan, 6',12'-dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))- (9CI); (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2(16,19).1(3,10).1(21,25).0(4,8).0(14,39).0(31,35)]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dodecaene; (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2??,??.1?,??.1??,??.0?,?.0??,??.0??,??]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dodecaene
Click to Show/Hide
|
||||
Species Origin | Stephania delavayi ... | Click to Show/Hide | |||
Stephania delavayi | |||||
Disease | Hepatocellular carcinoma [ICD-11: 2C12] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C37H38N2O6
|
||||
PubChem CID | |||||
Canonical SMILES |
CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
|
||||
InChI |
1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1
|
||||
InChIKey |
YVPXVXANRNDGTA-WDYNHAJCSA-N
|
||||
CAS Number |
CAS 481-49-2
|
||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
S-1 | Gastrointestinal stromal tumor | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | DPYD | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | TYMS | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HSC-2 | CVCL_1287 | Oral cavity squamous cell carcinoma | Homo sapiens | ||
B88 | Oral squamous cell carcinoma | Homo sapiens | ||||
In-vivo Model | B88 or HSC2 cells (1*106) were suspended in 0.1 mL of serum-free medium and injected into the subcutaneous tissue of 5-week-old nude mice. | |||||
Experimental
Result(s) |
Combined therapy of cepharanthine and S-1 exerted antitumor effects on human OSCC xenografts markedly and significantly induced apoptotic cells in tumors treated with cepharanthine plus S-1. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Cathepsin B (CTSB) | Molecule Info | [3] | |
Cathepsin D (CTSD) | Molecule Info | [3] | ||
Eukaryotic translation initiation factor 2A (MYO1C) | Molecule Info | [4] | ||
Eukaryotic translation initiation factor 5A-1-like (NPC1) | Molecule Info | [5] | ||
BioCyc | Thyroid hormone biosynthesis | Click to Show/Hide | ||
KEGG Pathway | Sphingolipid signaling pathway | Click to Show/Hide | ||
2 | Lysosome | |||
3 | Tuberculosis | |||
4 | Antigen processing and presentation | |||
NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
Pathway Interaction Database | LKB1 signaling events | Click to Show/Hide | ||
2 | Ceramide signaling pathway | |||
3 | Direct p53 effectors | |||
4 | Validated nuclear estrogen receptor alpha network | |||
Reactome | Collagen degradation | Click to Show/Hide | ||
2 | Metabolism of Angiotensinogen to Angiotensins | |||
3 | MHC class II antigen presentation | |||
4 | Trafficking and processing of endosomal TLR | |||
5 | Assembly of collagen fibrils and other multimeric structures |